NVAX Valuation

Novavax Inc

Add to Watchlist

Advanced Chart

7.910

-0.49(-5.833%)1D

NVAX Relative Valuation

NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVAX is overvalued; if below, it's undervalued.

Historical Valuation

Novavax Inc (NVAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.40 is considered Overvalued compared with the five-year average of 0.22. The fair price of Novavax Inc (NVAX) is between 4.30 to 7.57 according to relative valuation methord. Compared to the current price of 7.91 USD , Novavax Inc is Overvalued By 4.48%.

Relative Value

Fair Zone

4.30-7.57

Current Price：7.91

4.48%

Overvalued

-4.34

Trailing

Forward

5.74

EV/EBITDA

Novavax Inc. (NVAX) has a current EV/EBITDA of 5.74. The 5-year average EV/EBITDA is -13.15. The thresholds are as follows: Strongly Undervalued below -138.46, Undervalued between -138.46 and -75.80, Fairly Valued between 49.51 and -75.80, Overvalued between 49.51 and 112.17, and Strongly Overvalued above 112.17. The current Forward EV/EBITDA of 5.74 falls within the Historic Trend Line -Fairly Valued range.

-4.56

EV/EBIT

Novavax Inc. (NVAX) has a current EV/EBIT of -4.56. The 5-year average EV/EBIT is 1.06. The thresholds are as follows: Strongly Undervalued below -30.48, Undervalued between -30.48 and -14.71, Fairly Valued between 16.84 and -14.71, Overvalued between 16.84 and 32.61, and Strongly Overvalued above 32.61. The current Forward EV/EBIT of -4.56 falls within the Historic Trend Line -Fairly Valued range.

8.40

Novavax Inc. (NVAX) has a current PS of 8.40. The 5-year average PS is 2.65. The thresholds are as follows: Strongly Undervalued below -1.69, Undervalued between -1.69 and 0.48, Fairly Valued between 4.81 and 0.48, Overvalued between 4.81 and 6.98, and Strongly Overvalued above 6.98. The current Forward PS of 8.40 falls within the Strongly Overvalued range.

-7.26

P/OCF

Novavax Inc. (NVAX) has a current P/OCF of -7.26. The 5-year average P/OCF is -15.67. The thresholds are as follows: Strongly Undervalued below -140.80, Undervalued between -140.80 and -78.23, Fairly Valued between 46.90 and -78.23, Overvalued between 46.90 and 109.47, and Strongly Overvalued above 109.47. The current Forward P/OCF of -7.26 falls within the Historic Trend Line -Fairly Valued range.

24.31

P/FCF

Novavax Inc. (NVAX) has a current P/FCF of 24.31. The 5-year average P/FCF is 24.66. The thresholds are as follows: Strongly Undervalued below -207.17, Undervalued between -207.17 and -91.25, Fairly Valued between 140.58 and -91.25, Overvalued between 140.58 and 256.49, and Strongly Overvalued above 256.49. The current Forward P/FCF of 24.31 falls within the Historic Trend Line -Fairly Valued range.

Novavax Inc (NVAX) has a current Price-to-Book (P/B) ratio of 36.20. Compared to its 3-year average P/B ratio of 1.33 , the current P/B ratio is approximately 2616.84% higher. Relative to its 5-year average P/B ratio of 8.70, the current P/B ratio is about 316.23% higher. Novavax Inc (NVAX) has a Forward Free Cash Flow (FCF) yield of approximately -0.46%. Compared to its 3-year average FCF yield of -59.18%, the current FCF yield is approximately -99.22% lower. Relative to its 5-year average FCF yield of -37.43% , the current FCF yield is about -98.77% lower.

36.20

P/B

Median3y

1.33

Median5y

8.70

-0.46

FCF Yield

Median3y

-59.18

Median5y

-37.43

Competitors Valuation Multiple

The average P/S ratio for NVAX's competitors is 18.21, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of 8.40, which is -53.88% above the industry average. Given its robust revenue growth of -42.42%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Intellia Therapeutics Inc

Taysha Gene Therapies Inc

Enliven Therapeutics Inc

23.42

1.18B

DNTH.O

Dianthus Therapeutics Inc

Performance Decomposition

Market capitalization of NVAX decreased by 9.29% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.77 to 3.30.

The secondary factor is the Margin Expansion, contributed 13.92%to the performance.

Overall, the performance of NVAX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-42.42%

415.48M → 239.24M

Revenue Growth

13.92%

39.08 → 44.52

Margin Expansion

19.21%

2.77 → 3.30

P/E Change

-9.29%